• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    IDEXX Laboratories (IDXX) Could Be 26% Undervalued Following UK Faecal Dx Expansion

    Simply Wall St·09/24/2026 06:25:36
    Listen to the news

    IDEXX Laboratories stock and the Faecal Dx expansion trigger

    IDEXX Laboratories (IDXX) recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection. This development reflects an increased emphasis on encouraging recurring use of its diagnostic solutions.

    Against that product backdrop, IDEXX Laboratories has had a tougher run in the market, with the share price down 22.09% year to date, despite a 19.49% gain in three year total shareholder return that still leaves the one year total shareholder return lower by 16.77%.

    Spot other veterinary and diagnostics stocks that could be setting up for the next leg higher with our hand picked 16 high quality undiscovered gems aligned to recurring revenue and strong fundamentals.

    The recent slide in IDEXX Laboratories looks less like a verdict on Faecal Dx and more like a reset in expectations. Is the current valuation now more about sentiment than the underlying veterinary diagnostics engine?

    Most Popular Narrative: 26% Undervalued

    The prevailing narrative has IDEXX Laboratories valued at $709.14 per share, compared with a last close of $522.02. This frames Faecal Dx within a broader recurring diagnostics story rather than a one off headline.

    Expansion in innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand. This is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

    See why 25 investors see IDEXX Laboratories as 26% undervalued.

    Result: Fair Value of $709.14 (UNDERVALUED)

    Still, if U.S. vet visit softness persists and international clinics adopt IDEXX Laboratories diagnostics more slowly, that 26% undervalued narrative could unravel quickly.

    Find out about the key risks to this IDEXX Laboratories narrative.

    Another view on IDEXX Laboratories valuation

    The first story has IDEXX Laboratories looking undervalued against a $709.14 fair value estimate. A simpler lens tells a different story. At a P/E of 36.1x compared with a fair ratio of 29.7x, the shares look expensive, and they also trade above peers at 33.8x. Which signal carries more weight for you?

    That richer P/E against both the fair ratio and the industry suggests less room for error if growth or margins disappoint, so it helps to see how the current price stacks up in a fuller breakdown of earnings multiples and assumptions. See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:IDXX P/E Ratio as at Sep 2026
    NasdaqGS:IDXX P/E Ratio as at Sep 2026

    Next Steps

    Mixed signals on IDEXX Laboratories valuation and sentiment do not have to leave you stuck on the sidelines. Move quickly, test the assumptions against your own research, and weigh the 4 key rewards and 1 important warning sign in 4 key rewards and 1 important warning sign.

    Looking for more IDEXX Laboratories style investment ideas?

    If IDEXX Laboratories has you thinking about quality and pricing power, it is worth lining up a few other watchlist candidates using structured screeners.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.